Patient Affairs Staff
Enhancing FDA Patient Engagement

Andrea Furia-Helms, MPH
Acting Director, Patient Affairs Staff
Office of Medical Programs and Tobacco
Office of the Commissioner
Patient Affairs Staff (PAS)

• Established December 2017
• Works closely with the medical product centers and other offices to support and complement patient engagement efforts
• Reports into the Principal Deputy Commissioner for Medical Products and Tobacco
Patient Engagement Collaborative
Patient Engagement Collaborative (PEC)

The FDA and the Clinical Trials Transformation Initiative (CTTI) are establishing an external group of patient organization and individual representatives to discuss topics about enhancing patient engagement in medical product development and regulatory discussions at FDA.
Why PEC?

- FDA listened
  - Public comments from patients and other stakeholders recommended that FDA create an outside group to provide input on patient engagement across the FDA

- The laws
  - Facilitated by recent legislation in both the 21st Century Cures Act and FDARA for fostering patient participation and incorporating patient experiences in the regulatory process

- A model
  - The European Medicines Agency’s Patients’ and Consumers’ Working Party (PCWP)
Patient Engagement Collaborative (PEC)

Membership Criteria

• Patients who have personal disease experience
• Caregivers who support patients, such as a parent, child, partner, other family member, or friend, and who have personal disease experience through this caregiver role
• Representatives from patient groups who, through their role in the patient group, have direct or indirect disease experience.
Patient Engagement Collaborative (PEC)

• Next Steps
  – 200 nominations received (closed January 29, 2018)
  – Review and select members
  – Schedule first meeting (TBD)

For more information:
FDA Voice Blog December 20, 2017
You Spoke, FDA Listened: New Patient Engagement Collaborative, Call for Nominations
Patient Experience Listening Sessions
Patient Experience Listening Sessions

- Memorandum of Understanding with the National Organization for Rare Disorders (NORD)
- Pilot listening sessions in rare diseases to enhance the incorporation of patient experience into regulatory discussions
- Assess value added to possibly expand
Patient Experience Listening Sessions

Next steps:
• Identify pilot therapeutic area
• Develop process with NORD
• Conduct pilot listening sessions
• Evaluate internal and external feedback
• Develop recommendations
Thank you

patientaffairs@fda.hhs.gov